HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nomifensine: effect in Parkinsonian patients not receiving levodopa.

Abstract
A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is an added feature.
AuthorsD M Park, L J Findley, G Hanks, M Sandler
JournalJournal of neurology, neurosurgery, and psychiatry (J Neurol Neurosurg Psychiatry) Vol. 44 Issue 4 Pg. 352-4 (Apr 1981) ISSN: 0022-3050 [Print] England
PMID7241163 (Publication Type: Journal Article)
Chemical References
  • Isoquinolines
  • Nomifensine
  • Levodopa
Topics
  • Aged
  • Double-Blind Method
  • Female
  • Humans
  • Isoquinolines (therapeutic use)
  • Levodopa (therapeutic use)
  • Male
  • Middle Aged
  • Nomifensine (therapeutic use)
  • Parkinson Disease (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: